P53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells

Journal of Cellular Biochemistry

Volumn 111, Issue 5, 2010, Pages 1280-1290

  Shen, Hong ^a   Maki, Carl G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

irradiation; Nutlin; p21; p53; PML nuclear bodies

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DOUBLE STRANDED DNA; HISTONE H2AX; NUTLIN 3; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL FRACTIONATION; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IONIZING RADIATION; IRRADIATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TELOMERE;

CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA REPAIR; HUMANS; IMIDAZOLES; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; OSTEOSARCOMA; PIPERAZINES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MDM2; TELOMERE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 78649854655     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22852     Document Type: Article

References (45)

1. Bakalkin G, Yakovleva T, Selivanova G, Magnusson KP, Szekely L, Kiseleva E, Klein G, Terenius L, Wiman KG,. 1994. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci USA 91: 413-417.
2. Bernardi R, Pandolfi PP,. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8: 1006-1016.
3. Boehme KA, Blattner C,. 2009. Regulation of p53-Insights into a complex process. Crit Rev Biochem Mol Biol 44: 367-392.
4. Borden KL,. 2002. Pondering the promyelocytic leukemia protein (PML) puzzle: Possible functions for PML nuclear bodies. Mol Cell Biol 22: 5259-5269.
5. Brown L, Boswell S, Raj L, Lee SW,. 2007. Transcriptional targets of p53 that regulate cellular proliferation. Crit Rev Eukaryot Gene Expr 17: 73-85.
6. Carbone R, Pearson M, Minucci S, Pelicci PG,. 2002. PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 21: 1633-1640.
7. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A,. 1991. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66: 675-684.
8. Dellaire G, Farrall R, Bickmore WA,. 2003. The Nuclear Protein Database (NPD): Sub-nuclear localisation and functional annotation of the nuclear proteome. Nucleic Acids Res 31: 328-330.
9. Di Leonardo A, Linke SP, Clarkin K, Wahl GM,. 1994. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540-2551.
10. Draskovic I, Arnoult N, Steiner V, Bacchetti S, Lomonte P, Londono-Vallejo A,. 2009. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination. Proc Natl Acad Sci USA 106: 15726-15731.
11. Everett RD, Lomonte P, Sternsdorf T, van Driel R, Orr A,. 1999. Cell cycle regulation of PML modification and ND10 composition. J Cell Sci 112: 4581-4588.
12. Fasching CL, Neumann AA, Muntoni A, Yeager TR, Reddel RR,. 2007. DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. Cancer Res 67: 7072-7077.
13. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW,. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14: 2015-2027.
14. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G,. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185-6195.
15. Goddard AD, Borrow J, Freemont PS, Solomon E,. 1991. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254: 1371-1374.
16. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP,. 2000. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730-736.
17. Haupt Y, Maya R, Kazaz A, Oren M,. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
18. Henson JD, Neumann AA, Yeager TR, Reddel RR,. 2002. Alternative lengthening of telomeres in mammalian cells. Oncogene 21: 598-610.
19. Horn HF, Vousden KH,. 2007. Coping with stress: Multiple ways to activate p53. Oncogene 26: 1306-1316.
20. Ichijima Y, Sakasai R, Okita N, Asahina K, Mizutani S, Teraoka H,. 2005. Phosphorylation of histone H2AX at M phase in human cells without DNA damage response. Biochem Biophys Res Commun 336: 807-812.
21. Jiang WQ, Zhong ZH, Henson JD, Reddel RR,. 2007. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 26: 4635-4647.
22. Jiang WQ, Zhong ZH, Nguyen A, Henson JD, Toouli CD, Braithwaite AW, Reddel RR,. 2009. Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. J Cell Biol 185: 797-810.
23. Kakizuka A, Miller WH, Jr., Umesono K, Warrell RP, Jr., Frankel SR, Murty VV, Dmitrovsky E, Evans RM,. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674.
24. Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, Juhlin L, Degos L, Calvo F, de The H,. 1995. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10: 1315-1324.
25. Kubbutat MH, Jones SN, Vousden KH,. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
26. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W,. 2004. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 101: 2259-2264.
27. Maki CG, Howley PM,. 1997. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 17: 355-363.
28. Maltzman W, Czyzyk L,. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4: 1689-1694.
29. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM,. 2003. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590.
30. Nagasawa H, Li CY, Maki CG, Imrich AC, Little JB,. 1995. Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res 55: 1842-1846.
31. Nagasawa H, Keng P, Maki C, Yu Y, Little JB,. 1998. Absence of a radiation-induced first-cycle G1-S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res 58: 2036-2041.
32. Pandolfi PP,. 2001. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet 10: 769-775.
33. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Grignani F, Pelicci PG,. 1991. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6: 1285-1292.
34. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG,. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210.
35. Rogakou EP, Boon C, Redon C, Bonner WM,. 1999. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146: 905-916.
36. Scheel C, Schaefer KL, Jauch A, Keller M, Wai D, Brinkschmidt C, van Valen F, Boecker W, Dockhorn-Dworniczak B, Poremba C,. 2001. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 20: 3835-3844.
37. Tanaka H, Mendonca MS, Bradshaw PS, Hoelz DJ, Malkas LH, Meyn MS, Gilley D,. 2005. DNA damage-induced phosphorylation of the human telomere-associated protein TRF2. Proc Natl Acad Sci USA 102: 15539-15544.
38. Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, Weichselbaum RR,. 2004. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 279: 2273-2280.
39. Tang W, Willers H, Powell SN,. 1999. p53 directly enhances rejoining of DNA double-strand breaks with cohesive ends in gamma-irradiated mouse fibroblasts. Cancer Res 59: 2562-2565.
40. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC, Vassilev LT,. 2004. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 279: 53015-53022.
41. Vaseva AV, Moll UM,. 2009. The mitochondrial p53 pathway. Biochim Biophys Acta 1787: 414-420.
42. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA,. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
43. Wu G, Jiang X, Lee WH, Chen PL,. 2003. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res 63: 2589-2595.
44. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR,. 1999. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59: 4175-4179.
45. Yu J, Lan J, Wang C, Wu Q, Zhu Y, Lai X, Sun J, Jin C, Huang H,. 2010. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells. Cancer Lett 291: 177-186.